810 results on '"Albain, Kathy S"'
Search Results
2. Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226
- Author
-
Rutherford, Delaney V, Medley, Sarah, Henderson, Nicholas C, Gersch, Christina L, Vandenberg, Ted A, Albain, Kathy S, Dakhil, Shaker R, Tirumali, Nagendra R, Gralow, Julie R, Hortobagyi, Gabriel N, Pusztai, Lajos, Mehta, Rita S, Hayes, Daniel F, Kidwell, Kelley M, Henry, N Lynn, Barlow, William E, Rae, James M, and Hertz, Daniel L
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Clinical Research ,Humans ,Female ,Anastrozole ,Fulvestrant ,Cytochrome P-450 CYP2C9 ,Cytochrome P-450 CYP3A ,Nitriles ,Triazoles ,Estradiol ,Genotype ,Breast Neoplasms ,Antineoplastic Agents ,Hormonal ,anastrozole ,drug-drug interaction ,fulvestrant ,metabolism ,pharmacogenetics ,pharmacokinetics ,drug–drug interaction ,Medical and Health Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
Objective & methods: This study tested associations of genotype-predicted activity of CYP3A4, other pharmacogenes, SLC28A7 (rs11648166) and ALPPL2 (rs28845026) with systemic concentrations of the endocrine therapies anastrozole and fulvestrant in SWOG S0226 trial participants. Results: Participants in the anastrozole-only arm with low CYP3A4 activity (i.e. CYP3A4*22 carriers) had higher systemic anastrozole concentrations than patients with high CYP3A4 activity (β-coefficient = 10.03; 95% CI: 1.42, 18.6; p = 0.025). In an exploratory analysis, participants with low CYP2C9 activity had lower anastrozole concentrations and higher fulvestrant concentrations than participants with high CYP2C9 activity. Conclusion: Inherited genetic variation in CYP3A4 and CYP2C9 may affect concentrations of endocrine therapy and may be useful to personalize dosing and improve treatment outcomes.
- Published
- 2023
3. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
- Author
-
Bergqvist, Mattias, Nordmark, Adrian, Williams, Amy, Paoletti, Costanza, Barlow, William, Cobain, Erin F, Mehta, Rita S, Gralow, Julie R, Hortobagyi, Gabriel N, Albain, Kathy S, Pusztai, Lajos, Sharma, Priyanka, Godwin, Andrew K, Thompson, Alastair M, Hayes, Daniel F, and Rae, James M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Cancer ,Breast Cancer ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Female ,Humans ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers ,Breast Neoplasms ,Prognosis ,Progression-Free Survival ,Receptor ,ErbB-2 ,Thymidine Kinase ,Thymidine kinase ,biomarker ,disease progression ,monitoring treatment ,breast cancer ,endocrine therapy ,Receptor ,erbB-2 ,Environmental Biotechnology ,Toxicology ,Bioinformatics and computational biology ,Medical biotechnology ,Environmental biotechnology - Abstract
BackgroundSome patients with metastatic breast cancer (MBC) stay on endocrine therapy (ET) for years and others progress quickly. Serum thymidine kinase activity (TKa), an indicator of cell-proliferation, is a potential biomarker for monitoring ET and predicting MBC outcome. We have previously reported TKa as being prognostic in MBC in SWOG S0226. Here, new data on progression within 30/60 days post sampling, with a new, FDA approved version of DiviTum®TKa highlighting differences vs. a Research Use Only version is reported.Methods1,546 serum samples from 454 patients were assessed, collected at baseline and at 4 subsequent timepoints during treatment. A new predefined cut-off tested the ability to predict disease progression. A new measuring unit, DuA (DiviTum® unit of Activity) is adopted.ResultsA DiviTum®TKa score
- Published
- 2023
4. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
- Author
-
Lang, Julie E, Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A, Chien, A Jo, Wallace, Anne M, Murthy, Rashmi, Albain, Kathy S, Ellis, Erin D, Beckwith, Heather, Haley, Barbara B, Elias, Anthony D, Boughey, Judy C, Yung, Rachel L, Isaacs, Claudine, Clark, Amy S, Han, Hyo S, Nanda, Rita, Khan, Qamar J, Edmiston, Kristen K, Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C, Brown-Swigart, Lamorna, Petricoin, Emanuel F, Wulfkuhle, Julia D, Buxton, Meredith, Clennell, Julia L, Sanil, Ashish, Berry, Scott, Asare, Smita M, Wilson, Amy, Hirst, Gillian L, Singhrao, Ruby, Asare, Adam L, Matthews, Jeffrey B, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S, Symmans, W Fraser, van 't Veer, Laura J, Hylton, Nola M, DeMichele, Angela M, Berry, Donald A, and Esserman, Laura J
- Subjects
Clinical Research ,Clinical Trials and Supportive Activities ,Prevention ,Breast Cancer ,Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions - Abstract
HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with high-risk early-stage breast cancer. I-SPY2 is a multicenter, phase II adaptively randomized neoadjuvant (NAC) clinical trial enrolling patients with stage II-III breast cancer with tumors 2.5 cm or larger on the basis of hormone receptors (HR), HER2 and Mammaprint status. Multiple novel investigational agents plus standard chemotherapy are evaluated in parallel for the primary endpoint of pathologic complete response (pCR). Patients with HER2-negative breast cancer were eligible for randomization to ganetespib from October 2014 to October 2015. Of 233 women included in the final analysis, 140 were randomized to the standard NAC control; 93 were randomized to receive 150 mg/m2 ganetespib every 3 weeks with weekly paclitaxel over 12 weeks, followed by AC. Arms were balanced for hormone receptor status (51-52% HR-positive). Ganetespib did not graduate in any of the biomarker signatures studied before reaching maximum enrollment. Final estimated pCR rates were 26% vs. 18% HER2-negative, 38% vs. 22% HR-negative/HER2-negative, and 15% vs. 14% HR-positive/HER2-negative for ganetespib vs control, respectively. The predicted probability of success in phase 3 testing was 47% HER2-negative, 72% HR-negative/HER2-negative, and 19% HR-positive/HER2-negative. Ganetespib added to standard therapy is unlikely to yield substantially higher pCR rates in HER2-negative breast cancer compared to standard NAC, and neither HSP90 pathway nor replicative stress expression markers predicted response. HSP90 inhibitors remain of limited clinical interest in breast cancer, potentially in other clinical settings such as HER2-positive disease or in combination with anti-PD1 neoadjuvant chemotherapy in triple negative breast cancer.Trial registration: www.clinicaltrials.gov/ct2/show/NCT01042379.
- Published
- 2022
5. Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
- Author
-
Paoletti, Costanza, Barlow, William E, Cobain, Erin F, Bergqvist, Mattias, Mehta, Rita S, Gralow, Julie R, Hortobagyi, Gabriel N, Albain, Kathy S, Pusztai, Lajos, Sharma, Priyanka, Godwin, Andrew K, Thompson, Alastair M, Hayes, Daniel F, and Rae, James M
- Subjects
Clinical Research ,Cancer ,Breast Cancer ,Rehabilitation ,Clinical Trials and Supportive Activities ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Hormonal ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Clinical Trials as Topic ,Female ,Humans ,Kaplan-Meier Estimate ,Middle Aged ,Prognosis ,Receptor ,ErbB-2 ,Receptors ,Estrogen ,Receptors ,Progesterone ,Retrospective Studies ,Thymidine Kinase ,Treatment Outcome ,Receptor ,erbB-2 ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeSerum thymidine kinase 1 (sTK1) activity is associated with poor prognosis in metastatic breast cancer (MBC). We assessed the prognostic effect of sTK1 in patients with hormone receptor-positive MBC treated on a prospective randomized trial of anastrozole (A) versus A plus fulvestrant (A + F).Patients and methodssTK1 was assessed in 1,726 serums [baseline (BL), cycles 2, 3, 4, and 7] using the DiviTum assay. A prespecified cutoff of ≥200 Du/L was considered high. Progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier, log-rank tests, and Cox regression.ResultsBL sTK1 was elevated in 171 (40%) of 432 patients. Patients with high versus low BL sTK1 had significantly worse PFS [median 11.2 vs. 17.3 months, HR = 1.76; 95% confidence interval (CI; 1.43-2.16); P < 0.0001] and OS [median 30 vs. 58 months, HR = 2.38; 95% CI (1.91-2.98); P < 0.0001]. OS was significantly better for patients with high sTK1 who did not have prior adjuvant tamoxifen and who received A + F versus A alone [median 46 vs. 21 months, HR = 0.58; 95% CI (0.38-0.87); P = 0.0087]. Patients with low sTK1 had no difference in outcomes by therapy (P = 0.44). At serial timepoints, high versus low sTK1 had significantly worse subsequent PFS and OS [at cycle 2: PFS HR = 1.70, 95% CI (1.34-2.17); P < 0.0001, OS HR = 2.51, 95% CI (1.93-3.26); P < 0.0001].ConclusionsHigh sTK1 at BL and subsequent timepoints is associated with worse prognosis in patients with MBC starting first-line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single-agent or combination ET.
- Published
- 2021
6. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
- Author
-
Clark, Amy S, Yau, Christina, Wolf, Denise M, Petricoin, Emanuel F, van 't Veer, Laura J, Yee, Douglas, Moulder, Stacy L, Wallace, Anne M, Chien, A Jo, Isaacs, Claudine, Boughey, Judy C, Albain, Kathy S, Kemmer, Kathleen, Haley, Barbara B, Han, Hyo S, Forero-Torres, Andres, Elias, Anthony, Lang, Julie E, Ellis, Erin D, Yung, Rachel, Tripathy, Debu, Nanda, Rita, Wulfkuhle, Julia D, Brown-Swigart, Lamorna, Gallagher, Rosa I, Helsten, Teresa, Roesch, Erin, Ewing, Cheryl A, Alvarado, Michael, Crane, Erin P, Buxton, Meredith, Clennell, Julia L, Paoloni, Melissa, Asare, Smita M, Wilson, Amy, Hirst, Gillian L, Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B, Berry, Scott, Sanil, Ashish, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S, Schwab, Richard B, Symmans, W Fraser, Hylton, Nola M, Berry, Donald A, Esserman, Laura J, and DeMichele, Angela M
- Subjects
Humans ,Breast Neoplasms ,Paclitaxel ,Maytansine ,Receptor ,erbB-2 ,Neoadjuvant Therapy ,Adult ,Aged ,Middle Aged ,Antibodies ,Monoclonal ,Humanized ,Biomarkers ,Tumor ,Trastuzumab ,Ado-Trastuzumab Emtansine ,Receptor ,ErbB-2 ,Clinical Trials and Supportive Activities ,Clinical Research ,Breast Cancer ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals - Abstract
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ado-trastuzumab emtansine plus pertuzumab (T-DM1/P) and paclitaxel, trastuzumab and pertuzumab (THP). Eligible women have >2.5 cm clinical stage II/III HER2+ breast cancer, adaptively randomized to T-DM1/P, THP, or a common control arm of paclitaxel/trastuzumab (TH), followed by doxorubicin/cyclophosphamide, then surgery. Both T-DM1/P and THP arms 'graduate' in all subtypes: predicted pCR rates are 63%, 72% and 33% for T-DM1/P (n = 52), THP (n = 45) and TH (n = 31) respectively. Toxicity burden is similar between arms. Degree of HER2 pathway signaling and phosphorylation in pretreatment biopsy specimens are associated with response to both T-DM1/P and THP and can further identify highly responsive HER2+ tumors to HER2-directed therapy. This may help identify patients who can safely de-escalate cytotoxic chemotherapy without compromising excellent outcome.
- Published
- 2021
7. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
- Author
-
Yee, Douglas, Isaacs, Claudine, Wolf, Denise M, Yau, Christina, Haluska, Paul, Giridhar, Karthik V, Forero-Torres, Andres, Jo Chien, A, Wallace, Anne M, Pusztai, Lajos, Albain, Kathy S, Ellis, Erin D, Beckwith, Heather, Haley, Barbara B, Elias, Anthony D, Boughey, Judy C, Kemmer, Kathleen, Yung, Rachel L, Pohlmann, Paula R, Tripathy, Debu, Clark, Amy S, Han, Hyo S, Nanda, Rita, Khan, Qamar J, Edmiston, Kristen K, Petricoin, Emanuel F, Stringer-Reasor, Erica, Falkson, Carla I, Majure, Melanie, Mukhtar, Rita A, Helsten, Teresa L, Moulder, Stacy L, Robinson, Patricia A, Wulfkuhle, Julia D, Brown-Swigart, Lamorna, Buxton, Meredith, Clennell, Julia L, Paoloni, Melissa, Sanil, Ashish, Berry, Scott, Asare, Smita M, Wilson, Amy, Hirst, Gillian L, Singhrao, Ruby, Asare, Adam L, Matthews, Jeffrey B, Hylton, Nola M, DeMichele, Angela, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S, Fraser Symmans, W, Van't Veer, Laura J, Berry, Donald A, and Esserman, Laura J
- Subjects
Diabetes ,Cancer ,Breast Cancer ,6.1 Pharmaceuticals - Abstract
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit function of the type I insulin-like growth factor receptor (IGF-1R). Ganitumab was tested in combination with metformin and paclitaxel (PGM) followed by AC compared to standard-of-care alone. While pathologic complete response (pCR) rates were numerically higher in the PGM treatment arm for hormone receptor-negative, HER2-negative breast cancer (32% versus 21%), this small increase did not meet I-SPY's prespecified threshold for graduation. PGM was associated with increased hyperglycemia and elevated hemoglobin A1c (HbA1c), despite the use of metformin in combination with ganitumab. We evaluated several putative predictive biomarkers of ganitumab response (e.g., IGF-1 ligand score, IGF-1R signature, IGFBP5 expression, baseline HbA1c). None were specific predictors of response to PGM, although several signatures were associated with pCR in both arms. Any further development of anti-IGF-1R therapy will require better control of anti-IGF-1R drug-induced hyperglycemia and the development of more predictive biomarkers.
- Published
- 2021
8. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)
- Author
-
Argiris, Athanassios, Miao, Jieling, Cristea, Mihaela C, Chen, Allen M, Sands, Jacob M, Decker, Roy H, Gettinger, Scott N, Daly, Megan E, Faller, Bryan A, Albain, Kathy S, Yanagihara, Ronald H, Garland, Linda L, Byers, Lauren A, Wang, Ding, Koczywas, Marianna, Redman, Mary W, Kelly, Karen, and Gandara, David R
- Subjects
Lung ,Lung Cancer ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,Rare Diseases ,Orphan Drug ,6.1 Pharmaceuticals ,6.5 Radiotherapy and other non-invasive therapies ,Evaluation of treatments and therapeutic interventions ,Aged ,Aged ,80 and over ,Antineoplastic Combined Chemotherapy Protocols ,Benzimidazoles ,Carboplatin ,Carcinoma ,Non-Small-Cell Lung ,Chemoradiotherapy ,Dose-Response Relationship ,Drug ,Female ,Humans ,Lung Neoplasms ,Male ,Middle Aged ,Neoplasm Staging ,Paclitaxel ,Progression-Free Survival ,Survival Rate ,NSCLC ,Thoracic radiotherapy ,PARP inhibitors ,carboplatin ,paclitaxel ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundWe conducted a 2-part study to evaluate the incorporation of veliparib, a PARP inhibitor, into chemoradiotherapy (CRT) for stage III non-small-cell lung cancer.Patients and methodsIn the phase I part, patients were treated successively at 3 dose levels of veliparib (40, 80, and 120 mg) twice daily during CRT. In the phase II part, patients were randomized to receive veliparib or placebo during thoracic radiotherapy with concurrent weekly carboplatin and paclitaxel, followed by 2 cycles of consolidation carboplatin and paclitaxel with veliparib or placebo. The study was prematurely discontinued owing to the emergence of adjuvant immunotherapy as standard of care.ResultsOf 21 patients enrolled in phase I, 2 patients developed dose-limiting toxicities (DLTs): 1 grade 3 esophagitis with dysphagia (at 40 mg) and 1 grade 3 esophagitis with dehydration (at 80 mg). No DLTs were seen at veliparib dose of 120 mg twice daily, which was selected for the phase II part that enrolled 31 eligible patients. Progression-free survival (PFS) was not different between the 2 arms (P = .20). For the veliparib and placebo arms, response rates were 56% and 69%, PFS at 1 year 47% and 46%, and overall survival at 1 year 89% and 54%, respectively.ConclusionVeliparib with CRT was feasible and well tolerated. Efficacy could not accurately be determined because of early study closure. Nonetheless, there is enthusiasm for the evaluation of PARP inhibitors in lung cancer as predictive biomarkers are being developed and combinations with immunotherapy are attractive.
- Published
- 2021
9. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
- Author
-
Chien, A Jo, Tripathy, Debasish, Albain, Kathy S, Symmans, W Fraser, Rugo, Hope S, Melisko, Michelle E, Wallace, Anne M, Schwab, Richard, Helsten, Teresa, Forero-Torres, Andres, Stringer-Reasor, Erica, Ellis, Erin D, Kaplan, Henry G, Nanda, Rita, Jaskowiak, Nora, Murthy, Rashmi, Godellas, Constantine, Boughey, Judy C, Elias, Anthony D, Haley, Barbara B, Kemmer, Kathleen, Isaacs, Claudine, Clark, Amy S, Lang, Julie E, Lu, Janice, Korde, Larissa, Edmiston, Kirsten K, Northfelt, Donald W, Viscusi, Rebecca K, Yee, Douglas, Perlmutter, Jane, Hylton, Nola M, Van't Veer, Laura J, DeMichele, Angela, Wilson, Amy, Peterson, Garry, Buxton, Meredith B, Paoloni, Melissa, Clennell, Julia, Berry, Scott, Matthews, Jeffrey B, Steeg, Katherine, Singhrao, Ruby, Hirst, Gillian L, Sanil, Ashish, Yau, Christina, Asare, Smita M, Berry, Donald A, and Esserman, Laura J
- Subjects
Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Prevention ,Breast Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Doxorubicin ,Female ,Heterocyclic Compounds ,3-Ring ,Humans ,Middle Aged ,Neoadjuvant Therapy ,Paclitaxel ,Protein Kinase Inhibitors ,Proto-Oncogene Proteins c-akt ,Receptor ,ErbB-2 ,Receptors ,Steroid ,Trastuzumab ,I-SPY 2 Consortium ,Receptor ,erbB-2 ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeThe phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer.Patients and methodsI-SPY 2 is a multicenter, phase II, open-label, adaptively randomized neoadjuvant platform trial that screens experimental therapies and efficiently identifies potential predictive biomarker signatures. Patients are categorized by human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), and MammaPrint statuses in a 2 × 2 × 2 layout. Patients within each of these 8 biomarker subtypes are adaptively randomly assigned to one of several experimental therapies, including MK-2206, or control. Therapies are evaluated for 10 biomarker signatures, each of which is a combination of these subtypes. The primary end point is pathologic complete response (pCR). A therapy graduates with one or more of these signatures if and when it has an 85% Bayesian predictive probability of success in a hypothetical phase III trial, adjusting for biomarker covariates. Patients in the current report received standard taxane- and anthracycline-based neoadjuvant therapy without (control) or with oral MK-2206 135 mg/week.ResultsMK-2206 graduated with 94 patients and 57 concurrently randomly assigned controls in 3 graduation signatures: HR-negative/HER2-positive, HR-negative, and HER2-positive. Respective Bayesian mean covariate-adjusted pCR rates and percentage probability that MK-2206 is superior to control were 0.48:0.29 (97%), 0.62:0.36 (99%), and 0.46:0.26 (94%). In exploratory analyses, MK-2206 evinced a numerical improvement in event-free survival in its graduating signatures. The most significant grade 3-4 toxicity was rash (14% maculopapular, 8.6% acneiform).ConclusionThe Akt inhibitor MK-2206 combined with standard neoadjuvant therapy resulted in higher estimated pCR rates in HR-negative and HER2-positive breast cancer. Although MK-2206 is not being further developed at this time, this class of agents remains of clinical interest.
- Published
- 2020
10. Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer
- Author
-
Khouzam, Matthew S., Wood, Douglas E., Vigneswaran, Wickii, Goyal, Amit, Czerlanis, Cheryl, Blackmon, Shanda H., Donington, Jessica, Albain, Kathy S., Freeman, Richard K., and Abdelsattar, Zaid M.
- Published
- 2023
- Full Text
- View/download PDF
11. Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): Survival differences in the context of race, gender and smoking.
- Author
-
Mack, Philip C., primary, Isa, Shun-ichi, additional, Hsieh, Ming-Hui, additional, Koh, Yasuhiro, additional, Moon, James, additional, Tamiya, Akihiro, additional, Redman, Mary Weber, additional, Albain, Kathy S., additional, Kelly, Karen, additional, Ambrosone, Christine B., additional, Gray, Jhanelle E., additional, Kubo, Akihito, additional, Gandara, David R., additional, Lara, Primo N, additional, and Kawaguchi, Tomoya, additional
- Published
- 2024
- Full Text
- View/download PDF
12. Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
- Author
-
Pusztai, Lajos, primary, Hoag, Jess R, additional, Albain, Kathy S., additional, Barlow, William E., additional, Stemmer, Salomon M., additional, Meisner, Allison, additional, Hortobagyi, Gabriel N., additional, Shak, Steven, additional, Hayes, Daniel F., additional, Rae, James M., additional, Baehner, Frederick, additional, Sharma, Priyanka, additional, and Kalinsky, Kevin, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.
- Author
-
Abdou, Yara, primary, Hoag, Jess R, additional, Barlow, William E., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K. L., additional, Dhesy-Thind, Sukhbinder K., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Racz, Jennifer M., additional, Tripathy, Debashish, additional, Hortobagyi, Gabriel N., additional, Pusztai, Lajos, additional, Sharma, Priyanka, additional, and Kalinsky, Kevin, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
- Author
-
Kalinsky, Kevin, primary, Barlow, William E., additional, Pathak, Harsh B, additional, Gralow, Julie R., additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K. L., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Shak, Steven, additional, Tripathy, Debashish, additional, Hortobagyi, Gabriel N., additional, Meric-Bernstam, Funda, additional, Sharma, Priyanka, additional, Pusztai, Lajos, additional, Thompson, Alastair Mark, additional, and Godwin, Andrew K., additional
- Published
- 2024
- Full Text
- View/download PDF
15. SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
- Author
-
Edelman, Martin J, Redman, Mary W, Albain, Kathy S, McGary, Eric C, Rafique, Noman M, Petro, Daniel, Waqar, Saiama N, Minichiello, Katherine, Miao, Jieling, Papadimitrakopoulou, Vassiliki A, Kelly, Karen, Gandara, David R, and Herbst, Roy S
- Subjects
Cancer ,Clinical Research ,Lung ,Genetics ,Clinical Trials and Supportive Activities ,Lung Cancer ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Biomarkers ,Tumor ,Bone Neoplasms ,Carcinoma ,Non-Small-Cell Lung ,Carcinoma ,Squamous Cell ,Cell Cycle Proteins ,Female ,Follow-Up Studies ,Gene Amplification ,Humans ,Lung Neoplasms ,Male ,Middle Aged ,Mutation ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Piperazines ,Pyridines ,Salvage Therapy ,Survival Rate ,Lung cancer ,Targeted therapy ,Squamous NSCLC ,Cell cycle gene alteration ,Cyclin-dependent kinase ,Master protocol ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
ObjectiveLung-MAP (SWOG S1400) is a master platform trial assessing targeted therapies in squamous NSCLC. The objective of study C (S1400C) was to evaluate the response rate to palbociclib, a cyclin-dependent kinase 4 and cyclin-dependent kinase 6 inhibitor, in patients with cell cycle gene abnormalities.MethodsPatients with squamous NSCLC, a performance status of 0 to 2, and normal organ function who had progressed after at least one prior platinum-based chemotherapy with cyclin-dependent kinase 4 gene (CDK4) or cyclin D1 gene (CCND1), cyclin D2 gene (CCND2), or cyclin D3 gene (CCND3) amplifications on tumor specimens were eligible. The study was originally designed as a phase II/III trial comparing palbociclib with docetaxel, but it was modified to a single-arm phase II trial with the primary end point of response when immunotherapy was approved. If two or fewer responses were seen in the first 20 patients, then the study would cease enrollment.ResultsA total of 88 patients (9% of patients screened) were assigned to S1400C, and 53 patients enrolled (including 17 to receive docetaxel). One patient who had been registered to receive docetaxel was re-registered to receive palbociclib after progression while taking docetaxel. The frequencies of cell cycle gene alterations in the eligible patients taking palbociclib (n = 32) were as follows: CCND1, 81% (n = 26); CCND2, 9% (n = 3); CCND3, 6% (n = 2); and CDK4, 3% (n = 1). In all, 32 eligible patients received palbociclib. There were two partial responses (response rate 6% [95% confidence interval (CI): 0%-15%]), both with CCND1 amplification. Twelve patients had stable disease (38% [95% CI: 21%-54%]). The median progression-free survival was 1.7 months (95% CI: 1.6-2.9 months) and the median overall survival was 7.1 months (95% CI: 4.2-12.5).ConclusionPalbociclib as monotherapy failed to demonstrate the prespecified criteria for advancement to phase III testing.
- Published
- 2019
16. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- Author
-
Tolaney, Sara M, Guo, Hao, Pernas, Sonia, Barry, William T, Dillon, Deborah A, Ritterhouse, Lauren, Schneider, Bryan P, Shen, Fei, Fuhrman, Kit, Baltay, Michele, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Mathew J, Shapira, Iuliana, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth, Partridge, Ann H, Hudis, Clifford A, Krop, Ian E, Burstein, Harold J, and Winer, Eric P
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Breast Cancer ,Clinical Trials and Supportive Activities ,Cancer ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Aged ,80 and over ,Breast Neoplasms ,Breast Neoplasms ,Male ,Chemotherapy ,Adjuvant ,Disease-Free Survival ,Female ,Follow-Up Studies ,Gene Expression Regulation ,Neoplastic ,Genetic Predisposition to Disease ,Genotype ,Humans ,Lymph Nodes ,Male ,Middle Aged ,Paclitaxel ,Peripheral Nervous System Diseases ,Poisson Distribution ,Polymorphism ,Single Nucleotide ,Receptor ,ErbB-2 ,Recurrence ,Risk ,Trastuzumab ,Treatment Outcome ,Receptor ,erbB-2 ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
PURPOSE:The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The primary analysis of the Adjuvant Paclitaxel and Trastuzumab trial demonstrated a 3-year disease-free survival (DFS) of 98.7%. In this planned secondary analysis, we report longer-term outcomes and exploratory results to characterize the biology of small HER2-positive tumors and genetic factors that may predispose to paclitaxel-induced peripheral neuropathy (TIPN). PATIENTS AND METHODS:In this phase II study, patients with HER2-positive breast cancer with tumors 3 cm or smaller and negative nodes received paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by trastuzumab for 9 months. The primary end point was DFS. Recurrence-free interval (RFI), breast cancer-specific survival, and overall survival (OS) were also analyzed. In an exploratory analysis, intrinsic subtyping by PAM50 (Prosigna) and calculation of the risk of recurrence score were performed on the nCounter analysis system on archival tissue. Genotyping was performed to investigate TIPN. RESULTS:A total of 410 patients were enrolled from October 2007 to September 2010. After a median follow-up of 6.5 years, there were 23 DFS events. The 7-year DFS was 93% (95% CI, 90.4 to 96.2) with four (1.0%) distant recurrences, 7-year OS was 95% (95% CI, 92.4 to 97.7), and 7-year RFI was 97.5% (95% CI, 95.9 to 99.1). PAM50 analyses (n = 278) showed that most tumors were HER2-enriched (66%), followed by luminal B (14%), luminal A (13%), and basal-like (8%). Genotyping (n = 230) identified one single-nucleotide polymorphism, rs3012437, associated with an increased risk of TIPN in patients with grade 2 or greater TIPN (10.4%). CONCLUSION:With longer follow-up, adjuvant paclitaxel and trastuzumab is associated with excellent long-term outcomes. Distribution of PAM50 intrinsic subtypes in small HER2-positive tumors is similar to that previously reported for larger tumors.
- Published
- 2019
17. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
- Author
-
Bellon, Jennifer R, Guo, Hao, Barry, William T, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Matthew, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth A, Partridge, Ann H, Hudis, Clifford A, Krop, Ian, Burstein, Harold J, Winer, Eric P, and Tolaney, Sara M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Breast Cancer ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Aged ,80 and over ,Breast Neoplasms ,Chemotherapy ,Adjuvant ,Female ,Humans ,Lymphatic Metastasis ,Mastectomy ,Segmental ,Middle Aged ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Paclitaxel ,Prospective Studies ,Radiotherapy ,Adjuvant ,Receptor ,ErbB-2 ,Survival Analysis ,Trastuzumab ,Treatment Outcome ,HER2 ,Stage I ,Local regional recurrence ,Breast cancer ,Receptor ,erbB-2 ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
PurposeWomen with HER2-positive breast cancer treated prior to effective anti-HER2 therapy have higher rates of local-regional recurrence (LRR) than those with HER2-negative disease. Effective systemic therapy, however, has been shown to decrease LRR. This study examines LRR in women with HER2-positive breast cancer treated on a single-arm prospective multicenter trial of adjuvant trastuzumab (H) and paclitaxel (T).MethodsPatients with HER2-positive tumors ≤ 3.0 cm with negative axillary nodes or micrometastatic disease were eligible. Systemic therapy included weekly T and H for 12 weeks followed by continuation of H to complete 1 year. Radiation therapy (RT) was required following breast-conserving surgery (BCS), but dose and fields were not specified. Disease-free survival (DFS) and LRR-free survival were calculated using the Kaplan-Meier method.ResultsOf the 410 patients enrolled from September 2007 to September 2010, 406 initiated protocol therapy and formed the basis of this analysis. A total of 272 (67%) had hormone receptor-positive tumors. Of 162 patients undergoing mastectomy, local therapy records were unavailable for two. None of the 160 for whom records were available received RT. Among 244 BCS patients, detailed RT records were available for 217 (89%). With a median follow-up of 6.5 years, 7-year DFS was 93.3% (95% CI 90.4-96.2), and LRR-free survival was 98.6% (95% CI 97.4-99.8).ConclusionLRR in this select group of early-stage patients with HER2-positive disease receiving effective anti-HER2 therapy is extremely low. If confirmed in additional studies, future investigational efforts should focus on de-escalating local therapy.
- Published
- 2019
18. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
- Author
-
Mehta, Rita S, Barlow, William E, Albain, Kathy S, Vandenberg, Ted A, Dakhil, Shaker R, Tirumali, Nagendra R, Lew, Danika L, Hayes, Daniel F, Gralow, Julie R, Linden, Hannah H, Livingston, Robert B, and Hortobagyi, Gabriel N
- Subjects
Estrogen ,Cancer ,Breast Cancer ,Patient Safety ,Clinical Trials and Supportive Activities ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Aged ,80 and over ,Anastrozole ,Antineoplastic Combined Chemotherapy Protocols ,Aromatase Inhibitors ,Breast Neoplasms ,Cross-Over Studies ,Estrogen Receptor Antagonists ,Female ,Follow-Up Studies ,Fulvestrant ,Humans ,Kaplan-Meier Estimate ,Middle Aged ,Neoplasm Metastasis ,Postmenopause ,Progression-Free Survival ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundWe previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy. We now report final survival outcomes.MethodsWe randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. Analysis of survival was performed by means of two-sided stratified log-rank tests and Cox regression. Efficacy and safety were compared between the two groups, both overall and in subgroups.ResultsOf 707 patients who had undergone randomization, 694 had data available for analysis. The combination-therapy group had 247 deaths among 349 women (71%) and a median overall survival of 49.8 months, as compared with 261 deaths among 345 women (76%) and a median overall survival of 42.0 months in the anastrozole-alone group, a significant difference (hazard ratio for death, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03 by the log-rank test). In a subgroup analysis of the two strata, overall survival among women who had not received tamoxifen previously was longer with the combination therapy than with anastrozole alone (median, 52.2 months and 40.3 months, respectively; hazard ratio, 0.73; 95% CI, 0.58 to 0.92); among women who had received tamoxifen previously, overall survival was similar in the two groups (median, 48.2 months and 43.5 months, respectively; hazard ratio, 0.97; 95% CI, 0.74 to 1.27) (P = 0.09 for interaction). The incidence of long-term toxic effects of grade 3 to 5 was similar in the two groups. Approximately 45% of the patients in the anastrozole-alone group crossed over to receive fulvestrant.ConclusionsThe addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.).
- Published
- 2019
19. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.
- Author
-
Moore, Halle CF, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances, Hitre, Erika, Moseley, Anna, Porter, David J, Francis, Prudence A, Goldstein, Lori J, Gomez, Henry L, Vallejos, Carlos S, Partridge, Ann H, Dakhil, Shaker R, Garcia, Agustin A, Gralow, Julie R, Lombard, Janine M, Forbes, John F, Martino, Silvana, Barlow, William E, Fabian, Carol J, Minasian, Lori M, Meyskens, Frank L, Gelber, Richard D, Hortobagyi, Gabriel N, and Albain, Kathy S
- Subjects
Cancer ,Aging ,Clinical Trials and Supportive Activities ,Breast Cancer ,Contraception/Reproduction ,Estrogen ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Reproductive health and childbirth ,Good Health and Well Being ,Adult ,Anthracyclines ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Cyclophosphamide ,Female ,Follow-Up Studies ,Goserelin ,Humans ,Menopause ,Premature ,Middle Aged ,Pregnancy ,Pregnancy Outcome ,Primary Ovarian Insufficiency ,Receptors ,Estrogen ,Survival Rate ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen. All statistical tests were two-sided. Of 257 patients, 218 were eligible and evaluable (105 in the chemotherapy + goserelin arm and 113 in the chemotherapy arm). More patients in the chemotherapy + goserelin arm reported at least one pregnancy vs the chemotherapy arm (5-year cumulative incidence = 23.1%, 95% confidence interval [CI] = 15.3% to 31.9%; and 12.2%, 95% CI = 6.8% to 19.2%, respectively; odds ratio = 2.34; 95% CI = 1.07 to 5.11; P = .03). Randomization to goserelin + chemotherapy was associated with a nonstatistically significant improvement in disease-free survival (hazard ratio [HR] = 0.55; 95% CI = 0.27 to 1.10; P = .09) and overall survival (HR = 0.45; 95% CI = 0.19 to 1.04; P = .06). In this long-term analysis of POEMS/S0230, we found continued evidence that patients randomly assigned to receive goserelin + chemotherapy were not only more likely to avoid premature menopause, but were also more likely to become pregnant without adverse effect on disease-related outcomes.
- Published
- 2019
20. Response to H. Nabi et al.
- Author
-
Cheng, Ting-Yuan David, Darke, Amy K, Redman, Mary W, Kelly, Karen, Santella, Regina M, Albain, Kathy S, and Ambrosone, Christine B
- Subjects
Carcinoma ,Non-Small-Cell Lung ,Humans ,Lung Neoplasms ,Smoking ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Published
- 2018
21. Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
- Author
-
Sparano, Joseph A., Crager, Michael, Gray, Robert J., Tang, Gong, Hoag, Jess, Baehner, Frederick L., Shak, Steven, Makower, Della F., Albain, Kathy S., Hayes, Daniel F., Geyer Jr., Charles E., Dees, Elizabeth C., Goetz, Matthew P., Olson Jr., John A., Lively, Tracy, Badve, Sunil S., Saphner, Thomas J., Whelan, Timothy J., Kaklamani, Virginia G., and Wolmark, Norman
- Subjects
BREAST cancer prognosis ,RISK assessment ,BIOLOGICAL models ,CANCER relapse ,GENOMICS ,BREAST tumors ,CHI-squared test ,DESCRIPTIVE statistics ,LONGITUDINAL method ,SURVIVAL analysis (Biometry) ,TUMOR classification ,COMPARATIVE studies ,CONFIDENCE intervals ,PROPORTIONAL hazards models ,OVERALL survival ,DISEASE risk factors - Abstract
Background: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative breast cancer. Its role, however, in providing prognostic information for late distant recurrence when added to clinicopathologic prognostic factors is unknown. Methods: A patient-specific meta-analysis including 10,004 women enrolled in three trials was updated using extended follow-up data from TAILORx, integrating the RS with histologic grade, tumor size, and age at surgery for the RSClin tool. Cox models integrating clinicopathologic factors and the RS were compared by using likelihood ratio (LR) tests. External validation of prognosis for distant recurrence in years 0 to 10 and 5 to 10 was performed in an independent cohort of 1098 women in a real-world registry. Results: RSClin provided significantly more prognostic information than either the clinicopathologic factors (ΔLR chi-square, 86.2; P<0.001) or RS alone (ΔLR chi-square, 131.0; P<0.001). The model was prognostic in an independent cohort for distant recurrence by 10 years after diagnosis (standardized hazard ratio, 1.56; 95% confidence interval, 1.25 to 1.94), was associated with late distant recurrence risk between 5 and 10 years after diagnosis (standardized hazard ratio, 1.78; 95% confidence interval, 1.25 to 2.55), and approximated the observed 10-year distant recurrence risk (Lin concordance, 0.87) and 5- to 10-year distant recurrence risk (Lin concordance, 0.92). Conclusions: The 21-gene RS is prognostic for distant recurrence and overall survival in early breast cancer. A model integrating the 21-gene RS and clinicopathologic factors improved estimates of distant recurrence risk compared with either used individually and stratified late distant recurrence risk. (Funded by the National Cancer Institute, National Institutes of Health [U10CA180820, U10CA180794, UG1CA189859, U10CA180868, and U10CA180822] and others.) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
- Author
-
Adamson, Kathi, Albain, Kathy S., Asare, Adam L., Asare, Smita M., Balassanian, Ron, Beckwith, Heather, Berry, Scott M., Berry, Donald A., Boughey, Judy C., Buxton, Meredith B., Chen, Yunn-Yi, Chen, Beiyun, Chien, A. Jo, Chui, Stephen Y., Clark, Amy S., Clennell, Julia L., Datnow, Brian, DeMichele, Angela M., Duan, Xiuzhen, Edmiston, Kirsten K., Elias, Anthony D., Ellis, Erin D., Esserman, Laura L., Euhus, David M., Fadare, Oluwole, Fan, Fang, Feldman, Michael D, Forero-Torres, Andres, Haley, Barbara B., Han, Hyo S., Harada, Shuko, Haugen, Patricia, Helsten, Teresa, Hirst, Gillian L., Hylton, Nola M., Isaacs, Claudine, Kemmer, Kathleen, Khan, Qamar J., Khazai, Laila, Klein, Molly E., Krings, Gregor, Lang, Julie E., LeBeau, Lauren G., Leyland-Jones, Brian, Liu, Minetta C., Lo, Shelly, Lu, Janice, Magliocco, Anthony, Matthews, Jeffrey B., Melisko, Michelle E., Mhawech-Fauceglia, Paulette, Moulder, Stacy L., Murthy, Rashmi K., Nanda, Rita, Northfelt, Donald W., Ocal, Idris T., Olopade, Olufunmilayo, Pambuccian, Stefan, Paoloni, Melissa, Park, John W., Parker, Barbara A., Perlmutter, Jane, Peterson, Garry, Pusztai, Lajos, Rendi, Mara, Rugo, Hope S., Sahoo, Sunati, Sams, Sharon, Sanil, Ashish, Sattar, Husain, Schwab, Richard B., Singhrao, Ruby, Steeg, Katherine, Stringer-Reasor, Erica, Symmans, W. Fraser, Tawfik, Ossama, Tripathy, Debasish, Troxell, Megan L., van't Veer, Laura J., Venters, Sara J., Vinh, Tuyethoa, Viscusi, Rebecca K., Wallace, Anne M., Wei, Shi, Wilson, Amy, Yau, Christina, Yee, Douglas, Zeck, Jay C., Osdoit, Marie, van der Noordaa, Marieke, Shad, Sonal, Wei, Jane, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, Martín, Miguel, del Monte-Millán, Maria, López-Tarruella, Sara, Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, Edge, Stephen B, Abraham, Jean E, Bartlett, John M S, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, Thomas, Jeremy S, Cameron, David, Graham, Ashley, Hall, Peter, Mackintosh, Lorna, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Kim, Mi-Ok, van 't Veer, Laura J, Esserman, Laura J, and Symmans, W Fraser
- Published
- 2022
- Full Text
- View/download PDF
23. Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)
- Author
-
Cheng, Ting-Yuan David, Darke, Amy K, Redman, Mary W, Zirpoli, Gary R, Davis, Warren, Ondracek, Rochelle Payne, Bshara, Wiam, Omilian, Angela R, Kratzke, Robert, Reid, Mary E, Molina, Julian R, Kolesar, Jill M, Chen, Yuhchyau, MacRae, Robert M, Moon, James, Mack, Philip, Gandara, David R, Kelly, Karen, Santella, Regina M, Albain, Kathy S, and Ambrosone, Christine B
- Subjects
Lung Cancer ,Prevention ,Estrogen ,Contraception/Reproduction ,Tobacco ,Lung ,Cancer ,Tobacco Smoke and Health ,Clinical Research ,Respiratory ,Adult ,Aged ,Aged ,80 and over ,Canada ,Carcinoma ,Non-Small-Cell Lung ,Female ,Humans ,Lung Neoplasms ,Male ,Middle Aged ,Receptors ,Steroid ,Sex Factors ,Smoking ,United States ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Background:To what extent steroid hormones contribute to lung cancer in male and female never smokers and smokers is unclear. We examined expression of hormone receptors in lung tumors by sex and smoking. Methods:Patients with primary non-small cell lung cancer were recruited into an Intergroup study in the United States and Canada, led by SWOG (S0424). Tumors from 813 cases (450 women and 363 men) were assayed using immunohistochemistry for estrogen receptor (ER)-α, ER-β, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Linear regression was used to examine differences in expression by sex and smoking status. Cox proportional hazard models were used to estimate survival associated with the receptors. All statistical tests were two-sided. Results:In ever smokers, postmenopause and oral contraceptive use were associated with lower nuclear ER-β (P = .02) and total (nuclear + cytoplasmic) PR expression (P = .02), respectively. Women had lower cytoplasmic ER-α (regression coefficient [β], or differences in H-scores = -15.8, P = .003) and nuclear ER-β (β = -12.8, P = .04) expression than men, adjusting for age, race, and smoking. Ever smokers had both higher cytoplasmic ER-α (β = 45.0, P < .001) and ER-β (β = 25.9, P < .001) but lower total PR (β = -42.1, P < .001) than never smokers. Higher cytoplasmic ER-α and ER-β were associated with worse survival (hazard ratio = 1.73, 95% confidence interval [CI] = 1.15 to 2.58, and HR = 1.59, 95% CI = 1.08 to 2.33, respectively; quartiles 4 vs 1). Conclusions:Lower expression of nuclear ER-β in women supports the estrogen hypothesis in lung cancer etiology. Increasing cytoplasmic ER-α and ER-β and decreasing PR protein expression may be mechanisms whereby smoking disrupts hormone pathways.
- Published
- 2018
24. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data
- Author
-
Lambertini, Matteo, Moore, Halle CF, Leonard, Robert CF, Loibl, Sibylle, Munster, Pamela, Bruzzone, Marco, Boni, Luca, Unger, Joseph M, Anderson, Richard A, Mehta, Keyur, Minton, Susan, Poggio, Francesca, Albain, Kathy S, Adamson, Douglas JA, Gerber, Bernd, Cripps, Amy, Bertelli, Gianfilippo, Seiler, Sabine, Ceppi, Marcello, Partridge, Ann H, and Del Mastro, Lucia
- Subjects
Breast Cancer ,Clinical Trials and Supportive Activities ,Contraception/Reproduction ,Cancer ,Clinical Research ,Aging ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adult ,Breast Neoplasms ,Disease-Free Survival ,Female ,Fertility Preservation ,Gonadotropin-Releasing Hormone ,Humans ,Organ Sparing Treatments ,Ovary ,Premenopause ,Primary Ovarian Insufficiency ,Randomized Controlled Trials as Topic ,Treatment Outcome ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic review and meta-analysis using individual patient-level data was conducted to better assess the efficacy and safety of this strategy in patients with early breast cancer. Methods The trials in which premenopausal women with early breast cancer were randomly assigned to receive (neo)adjuvant chemotherapy alone or with concurrent GnRHa were eligible for inclusion. Primary end points were premature ovarian insufficiency (POI) rate and post-treatment pregnancy rate. Disease-free survival and overall survival were secondary end points. Because each study represents a cluster, statistical analyses were performed using a random effects model. Results A total of 873 patients from five trials were included. POI rate was 14.1% in the GnRHa group and 30.9% in the control group (adjusted odds ratio, 0.38; 95% CI, 0.26 to 0.57; P < .001). A total of 37 (10.3%) patients had at least one post-treatment pregnancy in the GnRHa group and 20 (5.5%) in the control group (incidence rate ratio, 1.83; 95% CI, 1.06 to 3.15; P = .030). No significant differences in disease-free survival (adjusted hazard ratio, 1.01; 95% CI, 0.72 to 1.42; P = .999) and overall survival (adjusted hazard ratio, 0.67; 95% CI, 0.42 to 1.06; P = .083) were observed between groups. Conclusion Our findings provide evidence for the efficacy and safety of temporary ovarian suppression with GnRHa during chemotherapy as an available option to reduce the likelihood of chemotherapy-induced POI and potentially improve future fertility in premenopausal patients with early breast cancer.
- Published
- 2018
25. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
- Author
-
Sucheston-Campbell, Lara E, Clay-Gilmour, Alyssa I, Barlow, William E, Budd, G Thomas, Stram, Daniel O, Haiman, Christopher A, Sheng, Xin, Yan, Li, Zirpoli, Gary, Yao, Song, Jiang, Chen, Owzar, Kouros, Hershman, Dawn, Albain, Kathy S, Hayes, Daniel F, Moore, Halle C, Hobday, Timothy J, Stewart, James A, Rizvi, Abbas, Isaacs, Claudine, Salim, Muhammad, Gralow, Jule R, Hortobagyi, Gabriel N, Livingston, Robert B, Kroetz, Deanna L, and Ambrosone, Christine B
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Oncology and Carcinogenesis ,Peripheral Neuropathy ,Cancer ,Neurodegenerative ,Human Genome ,Neurosciences ,Clinical Research ,Breast Cancer ,2.1 Biological and endogenous factors ,Aetiology ,Black or African American ,Breast Neoplasms ,Bridged-Ring Compounds ,Female ,Genetic Predisposition to Disease ,Genome-Wide Association Study ,Genomics ,Genotype ,Humans ,Peripheral Nervous System Diseases ,Polymorphism ,Single Nucleotide ,Taxoids ,White People ,breast cancer ,genome-wide association study ,neuropathy ,taxane ,Pharmacology and Pharmaceutical Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
ObjectiveTaxane containing chemotherapy extends survival for breast cancer patients. However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or effectively treated. Using genome-wide analyses, we sought to identify common risk variants for TIPN.Patients and methodsWomen with high-risk breast cancer enrolled in SWOG 0221 were genotyped using the Illumina 1M chip. Genome-wide analyses were performed in relation to ≥grade 3 Common Terminology Criteria for Adverse Events (CTCAE) neuropathy in European and African Americans. Data were meta-analyzed with GW associations of CTCAE ≥grade 3 versus ResultsThe percentage of ≥grade 3 TIPN in 1269 European Americans and 139 African Americans in S0221, was 11.6 and 22.3%, respectively. CALGB 40101 ≥grade 3 TOPN was 7.2%. The most significant association with ≥grade 3 TIPN was the G allele of rs1858826 in GNGT1 (Pmeta=1.1×10), which showed a decrease in risk of ≥grade 3 TIPN (odds ratio=0.29, 95% confidence interval: 0.18-0.46).ConclusionThe genetic variants associated with ≥grade 3 TIPN are hypothesized to have biochemical functions and reside in and near genes involved in diabetes and diabetic neuropathy. This finding is consistent with results from CALGB 40101 pathway analyses. Larger homogeneous trials with similar dosing and criteria for defining neuropathy are needed to properly assess the relationship of genomics with the neuropathy spectrum.
- Published
- 2018
26. Supplementary Table S3 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
- Author
-
Albain, Kathy S., primary, Yau, Christina, primary, Petricoin, Emanuel F., primary, Wolf, Denise M., primary, Lang, Julie E., primary, Chien, A. Jo, primary, Haddad, Tufia, primary, Forero-Torres, Andres, primary, Wallace, Anne M., primary, Kaplan, Henry, primary, Pusztai, Lajos, primary, Euhus, David, primary, Nanda, Rita, primary, Elias, Anthony D., primary, Clark, Amy S., primary, Godellas, Constantine, primary, Boughey, Judy C., primary, Isaacs, Claudine, primary, Tripathy, Debu, primary, Lu, Janice, primary, Yung, Rachel L., primary, Gallagher, Rosa I., primary, Wulfkuhle, Julia D., primary, Brown-Swigart, Lamorna, primary, Krings, Gregor, primary, Chen, Yunn Yi, primary, Potter, David A., primary, Stringer-Reasor, Erica, primary, Blair, Sarah, primary, Asare, Smita M., primary, Wilson, Amy, primary, Hirst, Gillian L., primary, Singhrao, Ruby, primary, Buxton, Meredith, primary, Clennell, Julia L., primary, Sanil, Ashish, primary, Berry, Scott, primary, Asare, Adam L., primary, Matthews, Jeffrey B., primary, DeMichele, Angela M., primary, Hylton, Nola M., primary, Melisko, Michelle, primary, Perlmutter, Jane, primary, Rugo, Hope S., primary, Symmans, W. Fraser, primary, van't Veer, Laura J., primary, Yee, Douglas, primary, Berry, Donald A., primary, and Esserman, Laura J., primary
- Published
- 2024
- Full Text
- View/download PDF
27. Data from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
- Author
-
Albain, Kathy S., primary, Yau, Christina, primary, Petricoin, Emanuel F., primary, Wolf, Denise M., primary, Lang, Julie E., primary, Chien, A. Jo, primary, Haddad, Tufia, primary, Forero-Torres, Andres, primary, Wallace, Anne M., primary, Kaplan, Henry, primary, Pusztai, Lajos, primary, Euhus, David, primary, Nanda, Rita, primary, Elias, Anthony D., primary, Clark, Amy S., primary, Godellas, Constantine, primary, Boughey, Judy C., primary, Isaacs, Claudine, primary, Tripathy, Debu, primary, Lu, Janice, primary, Yung, Rachel L., primary, Gallagher, Rosa I., primary, Wulfkuhle, Julia D., primary, Brown-Swigart, Lamorna, primary, Krings, Gregor, primary, Chen, Yunn Yi, primary, Potter, David A., primary, Stringer-Reasor, Erica, primary, Blair, Sarah, primary, Asare, Smita M., primary, Wilson, Amy, primary, Hirst, Gillian L., primary, Singhrao, Ruby, primary, Buxton, Meredith, primary, Clennell, Julia L., primary, Sanil, Ashish, primary, Berry, Scott, primary, Asare, Adam L., primary, Matthews, Jeffrey B., primary, DeMichele, Angela M., primary, Hylton, Nola M., primary, Melisko, Michelle, primary, Perlmutter, Jane, primary, Rugo, Hope S., primary, Symmans, W. Fraser, primary, van't Veer, Laura J., primary, Yee, Douglas, primary, Berry, Donald A., primary, and Esserman, Laura J., primary
- Published
- 2024
- Full Text
- View/download PDF
28. Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
- Author
-
Albain, Kathy S., primary, Yau, Christina, primary, Petricoin, Emanuel F., primary, Wolf, Denise M., primary, Lang, Julie E., primary, Chien, A. Jo, primary, Haddad, Tufia, primary, Forero-Torres, Andres, primary, Wallace, Anne M., primary, Kaplan, Henry, primary, Pusztai, Lajos, primary, Euhus, David, primary, Nanda, Rita, primary, Elias, Anthony D., primary, Clark, Amy S., primary, Godellas, Constantine, primary, Boughey, Judy C., primary, Isaacs, Claudine, primary, Tripathy, Debu, primary, Lu, Janice, primary, Yung, Rachel L., primary, Gallagher, Rosa I., primary, Wulfkuhle, Julia D., primary, Brown-Swigart, Lamorna, primary, Krings, Gregor, primary, Chen, Yunn Yi, primary, Potter, David A., primary, Stringer-Reasor, Erica, primary, Blair, Sarah, primary, Asare, Smita M., primary, Wilson, Amy, primary, Hirst, Gillian L., primary, Singhrao, Ruby, primary, Buxton, Meredith, primary, Clennell, Julia L., primary, Sanil, Ashish, primary, Berry, Scott, primary, Asare, Adam L., primary, Matthews, Jeffrey B., primary, DeMichele, Angela M., primary, Hylton, Nola M., primary, Melisko, Michelle, primary, Perlmutter, Jane, primary, Rugo, Hope S., primary, Symmans, W. Fraser, primary, van't Veer, Laura J., primary, Yee, Douglas, primary, Berry, Donald A., primary, and Esserman, Laura J., primary
- Published
- 2024
- Full Text
- View/download PDF
29. Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
- Author
-
Albain, Kathy S., primary, Yau, Christina, primary, Petricoin, Emanuel F., primary, Wolf, Denise M., primary, Lang, Julie E., primary, Chien, A. Jo, primary, Haddad, Tufia, primary, Forero-Torres, Andres, primary, Wallace, Anne M., primary, Kaplan, Henry, primary, Pusztai, Lajos, primary, Euhus, David, primary, Nanda, Rita, primary, Elias, Anthony D., primary, Clark, Amy S., primary, Godellas, Constantine, primary, Boughey, Judy C., primary, Isaacs, Claudine, primary, Tripathy, Debu, primary, Lu, Janice, primary, Yung, Rachel L., primary, Gallagher, Rosa I., primary, Wulfkuhle, Julia D., primary, Brown-Swigart, Lamorna, primary, Krings, Gregor, primary, Chen, Yunn Yi, primary, Potter, David A., primary, Stringer-Reasor, Erica, primary, Blair, Sarah, primary, Asare, Smita M., primary, Wilson, Amy, primary, Hirst, Gillian L., primary, Singhrao, Ruby, primary, Buxton, Meredith, primary, Clennell, Julia L., primary, Sanil, Ashish, primary, Berry, Scott, primary, Asare, Adam L., primary, Matthews, Jeffrey B., primary, DeMichele, Angela M., primary, Hylton, Nola M., primary, Melisko, Michelle, primary, Perlmutter, Jane, primary, Rugo, Hope S., primary, Symmans, W. Fraser, primary, van't Veer, Laura J., primary, Yee, Douglas, primary, Berry, Donald A., primary, and Esserman, Laura J., primary
- Published
- 2024
- Full Text
- View/download PDF
30. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
- Author
-
Ruddy, Kathryn J., Zheng, Yue, Tayob, Nabihah, Hu, Jiani, Dang, Chau T., Yardley, Denise A., Isakoff, Steven J., Valero, Vicente V., Faggen, Meredith G., Mulvey, Therese M., Bose, Ron, Sella, Tal, Weckstein, Douglas J., Wolff, Antonio C., Reeder-Hayes, Katherine E., Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan S., Hart, Lowell L., Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit L., Briccetti, Frederick M., Schneider, Bryan P., Merrill Garrett, A., Kelly Marcom, P., Albain, Kathy S., DeFusco, Patricia A., Tung, Nadine M., Ardman, Blair M., Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta C., Rosenberg, Shoshana, DeMeo, Michelle K., Burstein, Harold J., Winer, Eric P., Krop, Ian E., Partridge, Ann H., and Tolaney, Sara M.
- Published
- 2021
- Full Text
- View/download PDF
31. Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
- Author
-
Shatsky, Rebecca Arielle, Trivedi, Meghna S., Omene, Coral Oghenerukevwe, Kalinsky, Kevin, Roussos Torres, Evanthia T., Thomas, Brittani, Sanford, Amy, Albain, Kathy S., Clark, Amy Sanders, Falkson, Carla Isadora, Isaacs, Claudine, Thomas, Alexandra, Tseng, Jennifer, van 't Veer, Laura, Rugo, Hope S., Hylton, Nola, Yee, Douglas, Yau, Christina, and Esserman, Laura
- Published
- 2024
- Full Text
- View/download PDF
32. Adaptive Randomization of Neratinib in Early Breast Cancer
- Author
-
Park, John W, Liu, Minetta C, Yee, Douglas, Yau, Christina, van 't Veer, Laura J, Symmans, W Fraser, Paoloni, Melissa, Perlmutter, Jane, Hylton, Nola M, Hogarth, Michael, DeMichele, Angela, Buxton, Meredith B, Chien, A Jo, Wallace, Anne M, Boughey, Judy C, Haddad, Tufia C, Chui, Stephen Y, Kemmer, Kathleen A, Kaplan, Henry G, Isaacs, Claudine, Nanda, Rita, Tripathy, Debasish, Albain, Kathy S, Edmiston, Kirsten K, Elias, Anthony D, Northfelt, Donald W, Pusztai, Lajos, Moulder, Stacy L, Lang, Julie E, Viscusi, Rebecca K, Euhus, David M, Haley, Barbara B, Khan, Qamar J, Wood, William C, Melisko, Michelle, Schwab, Richard, Helsten, Teresa, Lyandres, Julia, Davis, Sarah E, Hirst, Gillian L, Sanil, Ashish, Esserman, Laura J, and Berry, Donald A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Breast Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adult ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Bayes Theorem ,Biomarkers ,Tumor ,Breast Neoplasms ,Female ,Humans ,Middle Aged ,Neoadjuvant Therapy ,Paclitaxel ,Quinolines ,Receptor ,ErbB-2 ,Receptors ,Estrogen ,Receptors ,Progesterone ,Trastuzumab ,I-SPY 2 Investigators ,Receptor ,erbB-2 ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundThe heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of pathological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time of surgery).MethodsWe used adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibitor neratinib with control. Eligible women were categorized according to eight biomarker subtypes on the basis of human epidermal growth factor receptor 2 (HER2) status, hormone-receptor status, and risk according to a 70-gene profile. Neratinib was evaluated against control with regard to 10 biomarker signatures (prospectively defined combinations of subtypes). The primary end point was pathological complete response. Volume changes on serial magnetic resonance imaging were used to assess the likelihood of such a response in each patient. Adaptive assignment to experimental groups within each disease subtype was based on Bayesian probabilities of the superiority of the treatment over control. Enrollment in the experimental group was stopped when the 85% Bayesian predictive probability of success in a confirmatory phase 3 trial of neoadjuvant therapy reached a prespecified threshold for any biomarker signature ("graduation"). Enrollment was stopped for futility if the probability fell to below 10% for every biomarker signature.ResultsNeratinib reached the prespecified efficacy threshold with regard to the HER2-positive, hormone-receptor-negative signature. Among patients with HER2-positive, hormone-receptor-negative cancer, the mean estimated rate of pathological complete response was 56% (95% Bayesian probability interval [PI], 37 to 73%) among 115 patients in the neratinib group, as compared with 33% among 78 controls (95% PI, 11 to 54%). The final predictive probability of success in phase 3 testing was 79%.ConclusionsNeratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer. (Funded by QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).
- Published
- 2016
33. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- Author
-
Rugo, Hope S, Olopade, Olufunmilayo I, DeMichele, Angela, Yau, Christina, van 't Veer, Laura J, Buxton, Meredith B, Hogarth, Michael, Hylton, Nola M, Paoloni, Melissa, Perlmutter, Jane, Symmans, W Fraser, Yee, Douglas, Chien, A Jo, Wallace, Anne M, Kaplan, Henry G, Boughey, Judy C, Haddad, Tufia C, Albain, Kathy S, Liu, Minetta C, Isaacs, Claudine, Khan, Qamar J, Lang, Julie E, Viscusi, Rebecca K, Pusztai, Lajos, Moulder, Stacy L, Chui, Stephen Y, Kemmer, Kathleen A, Elias, Anthony D, Edmiston, Kirsten K, Euhus, David M, Haley, Barbara B, Nanda, Rita, Northfelt, Donald W, Tripathy, Debasish, Wood, William C, Ewing, Cheryl, Schwab, Richard, Lyandres, Julia, Davis, Sarah E, Hirst, Gillian L, Sanil, Ashish, Berry, Donald A, and Esserman, Laura J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Genetics ,Breast Cancer ,Clinical Research ,Cancer ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Bayes Theorem ,Benzimidazoles ,Carboplatin ,Female ,Humans ,Middle Aged ,Neoadjuvant Therapy ,Paclitaxel ,Poly(ADP-ribose) Polymerase Inhibitors ,Triple Negative Breast Neoplasms ,I-SPY 2 Investigators ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundThe genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer. The goal is to match experimental regimens with responding cancer subtypes. We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carboplatin.MethodsIn this ongoing trial, women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter; cancers are categorized into eight biomarker subtypes on the basis of status with regard to human epidermal growth factor receptor 2 (HER2), hormone receptors, and a 70-gene assay. Patients undergo adaptive randomization within each biomarker subtype to receive regimens that have better performance than the standard therapy. Regimens are evaluated within 10 biomarker signatures (i.e., prospectively defined combinations of biomarker subtypes). Veliparib-carboplatin plus standard therapy was considered for HER2-negative tumors and was therefore evaluated in 3 signatures. The primary end point is pathological complete response. Tumor volume changes measured by magnetic resonance imaging during treatment are used to predict whether a patient will have a pathological complete response. Regimens move on from phase 2 if and when they have a high Bayesian predictive probability of success in a subsequent phase 3 neoadjuvant trial within the biomarker signature in which they performed well.ResultsWith regard to triple-negative breast cancer, veliparib-carboplatin had an 88% predicted probability of success in a phase 3 trial. A total of 72 patients were randomly assigned to receive veliparib-carboplatin, and 44 patients were concurrently assigned to receive control therapy; at the completion of chemotherapy, the estimated rates of pathological complete response in the triple-negative population were 51% (95% Bayesian probability interval [PI], 36 to 66%) in the veliparib-carboplatin group versus 26% (95% PI, 9 to 43%) in the control group. The toxicity of veliparib-carboplatin was greater than that of the control.ConclusionsThe process used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer. (Funded by the QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).
- Published
- 2016
34. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226
- Author
-
Hertz, Daniel L, Barlow, William E, Kidwell, Kelley M, Albain, Kathy S, Vandenberg, Ted A, Dakhil, Shaker R, Tirumali, Nagendra R, Livingston, Robert B, Gralow, Julie, Hayes, Daniel F, Hortobagyi, Gabriel N, Mehta, Rita S, and Rae, James M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Breast Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Anastrozole ,Breast Neoplasms ,Drug Interactions ,Estradiol ,Female ,Fulvestrant ,Humans ,Nitriles ,Triazoles ,anastrozole ,breast cancer ,drug interaction ,fulvestrant ,pharmacokinetics ,Pharmacology and Pharmaceutical Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
AimsIn the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer. Here we report a pharmacokinetic subset analysis investigating a possible drug interaction between anastrozole and fulvestrant.MethodsPost-menopausal patients with HR-positive metastatic breast cancer were randomized to anastrozole with or without concurrent fulvestrant. Blood samples were collected at 2, 4, 6 and 8 months, just prior to receiving the next dose of anastrozole and fulvestrant. Drug concentrations were measured via LC/MS-MS. Anastrozole concentration was compared in patients on anastrozole alone vs. patients on concomitant fulvestrant. Comparisons were made at each time point using parametric tests and over time using a linear mixed effects model.ResultsA total of 483 anastrozole concentration measurements were included, 224 samples from 64 patients on the anastrozole alone arm and 259 from 73 patients on the combination arm. The mean anastrozole concentration in the combination arm was significantly lower than that in the anastrozole alone arm at each sample collection time (all P
- Published
- 2016
35. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
- Author
-
Ganz, Patricia A, Cecchini, Reena S, Julian, Thomas B, Margolese, Richard G, Costantino, Joseph P, Vallow, Laura A, Albain, Kathy S, Whitworth, Patrick W, Cianfrocca, Mary E, Brufsky, Adam M, Gross, Howard M, Soori, Gamini S, Hopkins, Judith O, Fehrenbacher, Louis, Sturtz, Keren, Wozniak, Timothy F, Seay, Thomas E, Mamounas, Eleftherios P, and Wolmark, Norman
- Subjects
Biomedical and Clinical Sciences ,Health Services and Systems ,Health Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Behavioral and Social Science ,Clinical Research ,Aging ,Breast Cancer ,Clinical Trials and Supportive Activities ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Anastrozole ,Antineoplastic Agents ,Hormonal ,Aromatase Inhibitors ,Breast Neoplasms ,Carcinoma ,Ductal ,Breast ,Double-Blind Method ,Female ,Follow-Up Studies ,Humans ,Mastectomy ,Segmental ,Middle Aged ,Nitriles ,Postmenopause ,Quality of Life ,Tamoxifen ,Triazoles ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundThe NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drugs on quality of life and symptoms.MethodsThe study was done at 333 hospitals in North America. Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole breast irradiation were randomly assigned to receive either tamoxifen (20 mg/day) or anastrazole (1 mg/day) for 5 years, stratified by age (
- Published
- 2016
36. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
- Author
-
Margolese, Richard G, Cecchini, Reena S, Julian, Thomas B, Ganz, Patricia A, Costantino, Joseph P, Vallow, Laura A, Albain, Kathy S, Whitworth, Patrick W, Cianfrocca, Mary E, Brufsky, Adam M, Gross, Howard M, Soori, Gamini S, Hopkins, Judith O, Fehrenbacher, Louis, Sturtz, Keren, Wozniak, Timothy F, Seay, Thomas E, Mamounas, Eleftherios P, and Wolmark, Norman
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Breast Cancer ,Aging ,Digestive Diseases ,Estrogen ,Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Administration ,Oral ,Age Factors ,Anastrozole ,Antineoplastic Agents ,Hormonal ,Aromatase Inhibitors ,Breast Neoplasms ,Carcinoma ,Ductal ,Breast ,Combined Modality Therapy ,Double-Blind Method ,Embolism ,Female ,Humans ,Mastectomy ,Segmental ,Middle Aged ,Nitriles ,Postmenopause ,Tamoxifen ,Thrombosis ,Triazoles ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundDuctal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated that an aromatase inhibitor would be safer and more effective. We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.MethodsThe double-blind, randomised, phase 3 National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial was done in 333 participating NSABP centres in the USA and Canada. Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole-breast irradiation were enrolled and randomly assigned (1:1) to receive either oral tamoxifen 20 mg per day (with matching placebo in place of anastrozole) or oral anastrozole 1 mg per day (with matching placebo in place of tamoxifen) for 5 years. Randomisation was stratified by age (
- Published
- 2016
37. Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630
- Author
-
Potkul, Ronald K, Unger, Joseph M, Livingston, Robert B, Crew, Katherine D, Wilczynski, Sharon P, Salomon, Caryl G, Smith, Barbara L, Wong, Lucas, Campbell, David L, Einspahr, David E, Anderson, Garnet L, Hershman, Dawn, Goodman, Gary E, Brown, Powel H, Meyskens, Frank L, and Albain, Kathy S
- Subjects
Biomedical and Clinical Sciences ,Health Services and Systems ,Health Sciences ,Oncology and Carcinogenesis ,Reproductive Medicine ,Aging ,Clinical Trials and Supportive Activities ,Cancer ,Clinical Research ,Uterine Cancer ,Breast Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Clinical sciences ,Oncology and carcinogenesis ,Epidemiology - Abstract
The proliferative effect of adjuvant tamoxifen on the endometrium can potentially result in endometrial abnormalities, including cancer in postmenopausal women. We conducted a randomized, controlled trial to assess endometrial pathological diagnoses in postmenopausal women with early stage, ER-positive breast cancer without endometrial pathology at baseline. They were assigned to tamoxifen alone versus tamoxifen plus cyclical medroxyprogesterone acetate (MPA 10 mg for 14 days every 3 months) for 5 years. Endovaginal sonograms (EVS) +/- endometrial biopsies (EMB) were required at baseline, 2 and 5 years. Of 313 patients registered, 296 were eligible and 169 (57%; 89, tamoxifen; 80, tamoxifen+MPA) were evaluable (completed year-2 EVS, with an EMB if stripe width was ⩾5 mm). Sixty (67%) of these in the tamoxifen arm had an endometrial stripe width ⩾5 mm (and underwent subsequent EMB) compared with 48 (60%) in the tamoxifen+MPA arm (P=0.40). There were four cases of proliferative endometrium and one simple hyperplasia on the tamoxifen arm (6% (95% confidence interval (CI): 2-13%) among evaluable patients and one proliferative endometrium on the tamoxifen+MPA arm (P=0.11). The overall fraction with benign endometrial abnormalities at year 2 was 3.6% (6/169; 95% CI: 1.3-7.6%), with only 1 (of 102) new benign proliferative event at year 5. The event rate in both arms was much lower than projected, making treatment arm comparisons less informative. A normal endometrium prior to tamoxifen may provide reassurance regarding future endometrial events. However, validation in a larger trial is needed before changing practice in asymptomatic, postmenopausal women.
- Published
- 2016
38. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
- Author
-
Kyalwazi, Beverly, primary, Yau, Christina, additional, Campbell, Michael J., additional, Yoshimatsu, Toshio F., additional, Chien, A. Jo, additional, Wallace, Anne M., additional, Forero-Torres, Andres, additional, Pusztai, Lajos, additional, Ellis, Erin D., additional, Albain, Kathy S., additional, Blaes, Anne H., additional, Haley, Barbara B., additional, Boughey, Judy C., additional, Elias, Anthony D., additional, Clark, Amy S., additional, Isaacs, Claudine J., additional, Nanda, Rita, additional, Han, Hyo S., additional, Yung, Rachel L., additional, Tripathy, Debasish, additional, Edmiston, Kristen K., additional, Viscusi, Rebecca K., additional, Northfelt, Donald W., additional, Khan, Qamar J., additional, Asare, Smita M., additional, Wilson, Amy, additional, Hirst, Gillian L., additional, Lu, Ruixiao, additional, Symmans, William Fraser, additional, Yee, Douglas, additional, DeMichele, Angela M., additional, van ’t Veer, Laura J., additional, Esserman, Laura J., additional, and Olopade, Olufunmilayo I., additional
- Published
- 2023
- Full Text
- View/download PDF
39. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221
- Author
-
Chen, Ciao-Sin, primary, Zirpoli, Gary, additional, Barlow, William E., additional, Budd, G. Thomas, additional, McKiver, Bryan, additional, Pusztai, Lajos, additional, Hortobagyi, Gabriel N., additional, Albain, Kathy S., additional, Damaj, M. Imad, additional, Godwin, Andrew K., additional, Thompson, Alastair, additional, Henry, N. Lynn, additional, Ambrosone, Christine B., additional, Stringer, Kathleen A., additional, and Hertz, Daniel L., additional
- Published
- 2023
- Full Text
- View/download PDF
40. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
- Author
-
DeMichele, Angela, Yee, Douglas, Berry, Donald A, Albain, Kathy S, Benz, Christopher C, Boughey, Judy, Buxton, Meredith, Chia, Stephen K, Chien, Amy J, Chui, Stephen Y, Clark, Amy, Edmiston, Kirsten, Elias, Anthony D, Forero-Torres, Andres, Haddad, Tufia C, Haley, Barbara, Haluska, Paul, Hylton, Nola M, Isaacs, Claudine, Kaplan, Henry, Korde, Larissa, Leyland-Jones, Brian, Liu, Minetta C, Melisko, Michelle, Minton, Susan E, Moulder, Stacy L, Nanda, Rita, Olopade, Olufunmilayo I, Paoloni, Melissa, Park, John W, Parker, Barbara A, Perlmutter, Jane, Petricoin, Emanuel F, Rugo, Hope, Symmans, Fraser, Tripathy, Debasish, van't Veer, Laura J, Viscusi, Rebecca K, Wallace, Anne, Wolf, Denise, Yau, Christina, and Esserman, Laura J
- Subjects
Humans ,Breast Neoplasms ,Treatment Outcome ,Chemotherapy ,Adjuvant ,Neoadjuvant Therapy ,Female ,Clinical Trials as Topic ,Drug Discovery ,Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Breast Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
The many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the many new drugs and potential synergistic combinations, the neoadjuvant approach has been used to test benefit of drug combinations in clinical trials of primary breast cancer. A recent FDA-led meta-analysis showed that pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who have specific breast cancer subtypes. This meta-analysis motivated the FDA's draft guidance for using pCR as a surrogate endpoint in accelerated drug approval. Using pCR as a registration endpoint was challenged at ASCO 2014 Annual Meeting with the presentation of ALTTO, an adjuvant trial in HER2-positive breast cancer that showed a nonsignificant reduction in DFS hazard rate for adding lapatinib, a HER-family tyrosine kinase inhibitor, to trastuzumab and chemotherapy. This conclusion seemed to be inconsistent with the results of NeoALTTO, a neoadjuvant trial that found a statistical improvement in pCR rate for the identical lapatinib-containing regimen. We address differences in the two trials that may account for discordant conclusions. However, we use the FDA meta-analysis to show that there is no discordance at all between the observed pCR difference in NeoALTTO and the observed HR in ALTTO. This underscores the importance of appropriately modeling the two endpoints when designing clinical trials. The I-SPY 2/3 neoadjuvant trials exemplify this approach.
- Published
- 2015
41. Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)
- Author
-
Ruddy, Kathryn J, Guo, Hao, Barry, William, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Matthew J, Shapira, Iuliana, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth A, Hudis, Clifford, Krop, Ian E, Burstein, Harold J, Winer, Eric P, Partridge, Ann H, and Tolaney, Sara M
- Subjects
Clinical Research ,Prevention ,Breast Cancer ,Aging ,Cancer ,Contraception/Reproduction ,Estrogen ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Amenorrhea ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Chemotherapy ,Adjuvant ,Clinical Trials ,Phase II as Topic ,Female ,Follow-Up Studies ,Humans ,Middle Aged ,Neoplasm Grading ,Neoplasm Staging ,Paclitaxel ,Trastuzumab ,Tumor Burden ,Breast cancer ,Chemotherapy ,Fertility ,Premenopausal ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Chemotherapy-related amenorrhea (CRA) is associated with infertility and menopausal symptoms. Learning how frequently paclitaxel and trastuzumab cause amenorrhea is important. Most other adjuvant breast cancer therapies induce CRA in approximately 50 % of all premenopausal recipients [1]. 410 patients enrolled on the APT Trial, a single-arm phase 2 adjuvant study of 12 weeks of paclitaxel and trastuzumab followed by nine months of trastuzumab monotherapy. Eligible patients had ≤3 cm node-negative HER2 + breast cancers. Premenopausal enrollees were asked to complete menstrual surveys every 3-12 months for 72 months. Women who responded to at least one survey at least 15 months after chemotherapy initiation (and who did not undergo hysterectomy and/or bilateral oophorectomy or receive ovarian suppressing medications prior to 15 months) were included in this analysis. A participant was defined as having amenorrhea in follow-up if her self-reported last menstrual period at last follow-up was greater than 12 months prior to the survey. Among the 64 women in the evaluable population (median age at study entry 44 years, range 27-52 years), the median time between chemotherapy initiation and last menstrual survey was 51 months (range 16-79). 18 of 64 women (28 %, 95 % CI 18-41 %) were amenorrheic at that time point. Amenorrhea rates among premenopausal women treated with adjuvant paclitaxel and trastuzumab for early stage breast cancer appear lower than those seen historically with standard alkylator-based breast cancer regimens. Future studies are needed to understand the impact of this regimen on related issues of fertility and menopausal symptoms.
- Published
- 2015
42. Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy
- Author
-
Moore, Halle CF, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A, Goldstein, Lori J, Gomez, Henry L, Vallejos, Carlos S, Partridge, Ann H, Dakhil, Shaker R, Garcia, Agustin A, Gralow, Julie, Lombard, Janine M, Forbe, John F, Martino, Silvana, Barlow, William E, Fabian, Carol J, Minasian, Lori, Meyskens, Frank L, Gelber, Richard D, Hortobagyi, Gabriel N, and Albain, Kathy S
- Subjects
Clinical Trials and Supportive Activities ,Contraception/Reproduction ,Aging ,Rare Diseases ,Breast Cancer ,Clinical Research ,Cancer ,Estrogen ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Reproductive health and childbirth ,Paediatrics and Reproductive Medicine ,Obstetrics & Reproductive Medicine - Published
- 2015
43. Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors (SWOG S1008).
- Author
-
Greenlee, Heather, Lew, Danika, Hershman, Dawn L, Pierce, John P, Hansen, Lisa Kathryn, Newman, Vicky A, Korner, Judith, Sayegh, Antoine, Fehrenbacher, Louis, Lo, Shelly S, Klemp, Jennifer R, Rinn, Kristine, Robertson, John M, Unger, Joseph M, Gralow, Julie, Albain, Kathy S, Krouse, Robert S, and Fabian, Carol J
- Subjects
Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Published
- 2015
44. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- Author
-
Tolaney, Sara M, Barry, William T, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth A, Partridge, Ann H, Guo, Hao, Hudis, Clifford A, Krop, Ian E, Burstein, Harold J, and Winer, Eric P
- Subjects
Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Breast Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adenocarcinoma ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Chemotherapy ,Adjuvant ,Disease-Free Survival ,Female ,Follow-Up Studies ,Humans ,Infusions ,Intravenous ,Mastectomy ,Segmental ,Middle Aged ,Neoplasm Recurrence ,Local ,Paclitaxel ,Radiotherapy ,Receptor ,ErbB-2 ,Survival Rate ,Trastuzumab ,Receptor ,erbB-2 ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundNo single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.MethodsWe performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 weeks, followed by 9 months of trastuzumab monotherapy. The primary end point was survival free from invasive disease.ResultsThe median follow-up period was 4.0 years. The 3-year rate of survival free from invasive disease was 98.7% (95% confidence interval [CI], 97.6 to 99.8). Among the 12 relapses seen, 2 were due to distant metastatic breast cancer. Excluding contralateral HER2-negative breast cancers and nonbreast cancers, 7 disease-specific events were noted. A total of 13 patients (3.2%; 95% CI, 1.7 to 5.4) reported at least one episode of grade 3 neuropathy, and 2 had symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), both of whom had normalization of the left ventricular ejection fraction after discontinuation of trastuzumab. A total of 13 patients had significant asymptomatic declines in ejection fraction (3.2%; 95% CI, 1.7 to 5.4), as defined by the study, but 11 of these patients were able to resume trastuzumab therapy after a brief interruption.ConclusionsAmong women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT00542451.).
- Published
- 2015
45. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study
- Author
-
Larsen, Victoria, Barlow, William E., Yang, Jun J., Zhu, Qianqian, Liu, Song, Kwan, Marilyn L., Ergas, Isaac J., Roh, Janise M., Hutchins, Laura F., Kadlubar, Susan A., Albain, Kathy S., Rae, James M., Yeh, I-Tien, Ravdin, Peter M., Martino, Silvana, Lyss, Alan P., Osborne, C. Kent, Hortobagyi, Gabriel N., Kushi, Lawrence H., Hayes, Daniel F., Ambrosone, Christine B., and Yao, Song
- Published
- 2019
- Full Text
- View/download PDF
46. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).
- Author
-
Moore, Halle CF, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances M, Hitre, Erika, Porter, David James, Francis, Prudence A, Minasian, Lori M, Gelber, Richard D, Goldstein, Lori J, Gomez, Henry Leonidas, Vallejos, Carlos, Partridge, Ann H, Dakhil, Shaker R, Martino, Silvana, Barlow, William E, Fabian, Carol J, Meyskens, Frank L, Hortobagyi, Gabriel N, and Albain, Kathy S
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Clinical Trials and Supportive Activities ,Cancer ,Estrogen ,Clinical Research ,Contraception/Reproduction ,Breast Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Clinical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
LBA505 Background: Premature ovarian failure (POF) is a common toxicity of CT. Risk depends on type and amount of CT, age, and perhaps ovarian cycling at the time of CT. POEMS is a SWOG-coordinated phase III randomized study to evaluate whether LHRH analog administration with CT for early-stage breast cancer (BC) would reduce POF.Premenopausal patients (PT) age .05). POF rates were 22% in the standard arm and 8% in the GN arm (OR=0.30, 95% CI: 0.10-0.87, p=.03 [unadjusted analysis]; OR=0.36, 95%CI: 0.11-1.14, p=0.08 [adjusted logistic regression analysis]). In a sensitivity analysis defining 2-year POF more liberally as either amenorrhea or elevated FSH, 45% in the standard arm and 20% in the GN arm had POF (OR=0.29, 95% CI: 0.12-0.70, p=.006). There were 13 pregnancies in the standard arm and 22 in the GN arm (OR=2.22, 95% CI: 1.00-4.92, p=.05). DFS and OS were better in the GN arm (Cox regression, including stage: HR=0.49, 95% CI: 0.24-0.97, p=.04; HR=0.43, 95% CI: 0.18-1.00, p=.05, respectively).LHRH analog administration with CT was associated with less POF and more pregnancies. In an exploratory analysis, GN use in premenopausal ER-negative BC was associated with improved DFS and OS.NCT00068601.
- Published
- 2014
47. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).
- Author
-
Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances M, Hitre, Erika, Porter, David James, Francis, Prudence A, Minasian, Lori M, Gelber, Richard D, Goldstein, Lori J, Gomez, Henry Leonidas, Vallejos, Carlos, Partridge, Ann H, Dakhil, Shaker R, Martino, Silvana, Barlow, William E, Fabian, Carol J, Meyskens, Frank L, Hortobagyi, Gabriel N, and Albain, Kathy S
- Subjects
Oncology & Carcinogenesis ,Oncology and Carcinogenesis - Abstract
LBA505 Background: Premature ovarian failure (POF) is a common toxicity of CT. Risk depends on type and amount of CT, age, and perhaps ovarian cycling at the time of CT. POEMS is a SWOG-coordinated phase III randomized study to evaluate whether LHRH analog administration with CT for early-stage breast cancer (BC) would reduce POF.Premenopausal patients (PT) age .05). POF rates were 22% in the standard arm and 8% in the GN arm (OR=0.30, 95% CI: 0.10-0.87, p=.03 [unadjusted analysis]; OR=0.36, 95%CI: 0.11-1.14, p=0.08 [adjusted logistic regression analysis]). In a sensitivity analysis defining 2-year POF more liberally as either amenorrhea or elevated FSH, 45% in the standard arm and 20% in the GN arm had POF (OR=0.29, 95% CI: 0.12-0.70, p=.006). There were 13 pregnancies in the standard arm and 22 in the GN arm (OR=2.22, 95% CI: 1.00-4.92, p=.05). DFS and OS were better in the GN arm (Cox regression, including stage: HR=0.49, 95% CI: 0.24-0.97, p=.04; HR=0.43, 95% CI: 0.18-1.00, p=.05, respectively).LHRH analog administration with CT was associated with less POF and more pregnancies. In an exploratory analysis, GN use in premenopausal ER-negative BC was associated with improved DFS and OS.NCT00068601.
- Published
- 2014
48. Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
- Author
-
Chen, Ciao-Sin, primary, Zirpoli, Gary, additional, Budd, G. Thomas, additional, Barlow, William E., additional, Pusztai, Lajos, additional, Hortobagyi, Gabriel N., additional, Albain, Kathy S., additional, Godwin, Andrew K., additional, Thompson, Alastair, additional, Henry, N. Lynn, additional, Ambrosone, Christine B., additional, Stringer, Kathleen A., additional, and Hertz, Daniel L, additional
- Published
- 2023
- Full Text
- View/download PDF
49. Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement
- Author
-
Ganz, Patricia A, Yip, Cheng Har, Gralow, Julie R, Distelhorst, Sandra R, Albain, Kathy S, Andersen, Barbara L, Bevilacqua, Jose Luiz B, de Azambuja, Evandro, Saghir, Nagi S El, Kaur, Ranjit, McTiernan, Anne, Partridge, Ann H, Rowland, Julia H, Singh-Carlson, Savitri, Vargo, Mary M, Thompson, Beti, and Anderson, Benjamin O
- Subjects
Clinical Research ,Pain Research ,Health Services ,Breast Cancer ,Cancer ,Rehabilitation ,Mind and Body ,Prevention ,7.3 Management and decision making ,Management of diseases and conditions ,7.1 Individual care needs ,Quality Education ,Antineoplastic Agents ,Body Image ,Breast Neoplasms ,Depression ,Developing Countries ,Fatigue ,Female ,Health Personnel ,Humans ,Life Style ,Lymphedema ,Menopause ,Neoplasm Recurrence ,Local ,Pain Management ,Patient Education as Topic ,Postoperative Complications ,Resource Allocation ,Self Care ,Sexual Behavior ,Sleep Initiation and Maintenance Disorders ,Survivors ,Breast cancer ,Supportive care ,Survivorship ,Low- and middle-income countries ,Resource allocations ,Clinical Sciences ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
Breast cancer survivors may experience long-term treatment complications, must live with the risk of cancer recurrence, and often experience psychosocial complications that require supportive care services. In low- and middle-income settings, supportive care services are frequently limited, and program development for survivorship care and long-term follow-up has not been well addressed. As part of the 5th Breast Health Global Initiative (BHGI) Global Summit, an expert panel identified nine key resources recommended for appropriate survivorship care, and developed resource-stratified recommendations to illustrate how health systems can provide supportive care services for breast cancer survivors after curative treatment, using available resources. Key recommendations include health professional education that focuses on the management of physical and psychosocial long-term treatment complications. Patient education can help survivors transition from a provider-intense cancer treatment program to a post-treatment provider partnership and self-management program, and should include: education on recognizing disease recurrence or metastases; management of treatment-related sequelae, and psychosocial complications; and the importance of maintaining a healthy lifestyle. Increasing community awareness of survivorship issues was also identified as an important part of supportive care programs. Other recommendations include screening and management of psychosocial distress; management of long-term treatment-related complications including lymphedema, fatigue, insomnia, pain, and women's health issues; and monitoring survivors for recurrences or development of second primary malignancies. Where possible, breast cancer survivors should implement healthy lifestyle modifications, including physical activity, and maintain a healthy weight. Health professionals should provide well-documented patient care records that can follow a patient as they transition from active treatment to follow-up care.
- Published
- 2013
50. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
- Author
-
Hershman, Dawn L, Unger, Joseph M, Crew, Katherine D, Minasian, Lori M, Awad, Danielle, Moinpour, Carol M, Hansen, Lisa, Lew, Danika L, Greenlee, Heather, Fehrenbacher, Louis, Wade, James L, 3rd, Wong, Siu-Fun, Hortobagyi, Gabriel N, Meyskens, Frank L, and Albain, Kathy S
- Subjects
Acetylcarnitine: administration & dosage ,adverse effects ,Adult ,Aged ,Breast Neoplasms: drug therapy ,pathology ,surgery ,Chemotherapy ,Adjuvant ,Dietary Supplements ,Dose-Response Relationship ,Drug ,Double-Blind Method ,Drug Administration Schedule ,Female ,Follow-Up Studies ,Humans ,Linear Models ,Mastectomy: methods ,Middle Aged ,Multivariate Analysis ,Nerve Regeneration: drug effects ,Peripheral Nervous System Diseases: chemically induced ,prevention & control ,Reference Values ,Risk Assessment ,Sensitivity and Specificity ,Severity of Illness Index ,Taxoids: adverse effects ,therapeutic use ,Treatment Outcome ,acetylcarnitine ,taxoid ,adjuvant chemotherapy ,adult ,aged ,article ,breast tumor ,chemically induced disorder ,comparative study ,controlled clinical trial ,controlled study ,diet supplementation ,dose response ,double blind procedure ,drug administration ,drug effect ,female ,follow up ,human ,mastectomy ,methodology ,middle aged ,multivariate analysis ,nerve regeneration ,pathology ,peripheral neuropathy ,randomized controlled trial ,reference value ,risk assessment ,sensitivity and specificity ,severity of illness index ,statistical model ,treatment outcome ,Acetylcarnitine ,Adult ,Aged ,Breast Neoplasms ,Chemotherapy ,Adjuvant ,Dietary Supplements ,Dose-Response Relationship ,Drug ,Double-Blind Method ,Drug Administration Schedule ,Female ,Follow-Up Studies ,Humans ,Linear Models ,Mastectomy ,Middle Aged ,Multivariate Analysis ,Nerve Regeneration ,Peripheral Nervous System Diseases ,Reference Values ,Risk Assessment ,Sensitivity and Specificity ,Severity of Illness Index ,Taxoids ,Treatment Outcome - Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is common and leads to suboptimal treatment. Acetyl-L-carnitine (ALC) is a natural compound involved in neuronal protection. Studies have suggested ALC may be effective for the prevention and treatment of CIPN.A 24-week randomized double-blind trial comparing ALC (3,000 mg per day) with placebo in women undergoing adjuvant taxane-based chemotherapy was conducted. The primary objective was to determine if ALC prevents CIPN as measured by the 11-item neurotoxicity (NTX) component of the Functional Assessment of Cancer Therapy (FACT) -Taxane scale at 12 weeks. Secondary objectives included changes in 24-week end points, functional status (FACT-Trial Outcome Index [TOI]), fatigue (Functional Assessment of Chronic Illness Therapy [FACIT] -Fatigue), and NTX grade.A total of 409 patients were evaluable (208 received ALC; 201, placebo). In a multivariate linear regression, week-12 scores were 0.9 points lower (more CIPN) with ALC than placebo (95% CI, -2.2 to 0.4; P = .17), whereas week-24 scores were 1.8 points lower with ALC (95% CI, -3.2 to -0.4; P = .01). Patients receiving ALC were more likely to have a > 5-point decrease in FACT-NTX scores (38% v 28%; P = .05), and FACT-TOI scores were 3.5 points lower with ALC (P = .03). Grade 3 to 4 neurotoxicity was more frequent in the ALC arm (eight v one). No differences between arms were observed for FACIT-Fatigue or other toxicities. Serum carnitine level increased with ALC but remained stable with placebo.There was no evidence that ALC affected CIPN at 12 weeks; however, ALC significantly increased CIPN by 24 weeks. This is the first study to our knowledge showing that a nutritional supplement increased CIPN. Patients should be discouraged from using supplements without proven efficacy.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.